000124452 001__ 124452
000124452 005__ 20240228145515.0
000124452 0247_ $$2doi$$a10.1111/ejh.12888
000124452 0247_ $$2pmid$$apmid:28370401
000124452 0247_ $$2ISSN$$a0036-553X
000124452 0247_ $$2ISSN$$a0902-4441
000124452 0247_ $$2ISSN$$a1600-0609
000124452 0247_ $$2altmetric$$aaltmetric:18724649
000124452 037__ $$aDKFZ-2017-01329
000124452 041__ $$aeng
000124452 082__ $$a610
000124452 1001_ $$00000-0002-4000-6904$$aBaertsch, Marc-Andrea$$b0
000124452 245__ $$aCyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.
000124452 260__ $$aOxford$$bWiley-Blackwell$$c2017
000124452 3367_ $$2DRIVER$$aarticle
000124452 3367_ $$2DataCite$$aOutput Types/Journal article
000124452 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1509712506_7146
000124452 3367_ $$2BibTeX$$aARTICLE
000124452 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000124452 3367_ $$00$$2EndNote$$aJournal Article
000124452 520__ $$aAnalysis of the efficiency and toxicity of cyclophosphamide-based stem cell mobilization in patients with relapsed multiple myeloma (RMM).Peripheral blood stem cells (PBSCs) were mobilized with high dose cyclophosphamide (2 g/m(2) daily on days 1 and 2) and G-CSF plus pre-emptive/rescue plerixafor in RMM patients (first to third relapse) treated within the ReLApsE trial of the German-Speaking Myeloma Multicenter Group (GMMG).Mobilization was initiated with high-dose cyclophosphamide (HD-CY) and G-CSF in 30 patients. Fifteen patients received additional pre-emptive/rescue administration of plerixafor. Stem cell collection was successful (≥2×10(6) CD34+ cells per kg bw) in 77% (23/30 patients). Patients with prior high-dose melphalan collected a significantly lower median total number of PBSCs than patients without prior high-dose melphalan (3.3×10(6) vs 17×10(6) CD34+ cells/kg bw). Toxicity of HD-CY was frequent with 12 serious adverse events (SAE) in 37% of patients (11/30 patients). Infections accounted for the majority of SAE reports. In two patients, SAEs were lethal (septic shock).These data proof feasibility of PBSC collection at relapse but emphasize the importance of collection and storage of additional PBSC transplants during first-line treatment when mobilization is more efficient and less toxic.
000124452 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000124452 588__ $$aDataset connected to CrossRef, PubMed,
000124452 7001_ $$aSchlenzka, Jana$$b1
000124452 7001_ $$aLisenko, Katharina$$b2
000124452 7001_ $$0P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9$$aKrzykalla, Julia$$b3$$udkfz
000124452 7001_ $$0P:(DE-He78)ecb33fb615e08035fdcefcaebfdff8f0$$aBecker, Natalia$$b4$$udkfz
000124452 7001_ $$aWeisel, Katja$$b5
000124452 7001_ $$aNoppeney, Richard$$b6
000124452 7001_ $$aMartin, Hans$$b7
000124452 7001_ $$aLindemann, Hans W$$b8
000124452 7001_ $$aHaenel, Mathias$$b9
000124452 7001_ $$aNogai, Axel$$b10
000124452 7001_ $$aScheid, Christof$$b11
000124452 7001_ $$aSalwender, Hans$$b12
000124452 7001_ $$aFenk, Roland$$b13
000124452 7001_ $$aGraeven, Ullrich$$b14
000124452 7001_ $$aReimer, Peter$$b15
000124452 7001_ $$aSchmidt-Hieber, Martin$$b16
000124452 7001_ $$aGoerner, Martin$$b17
000124452 7001_ $$aSchmidt-Wolf, Ingo G H$$b18
000124452 7001_ $$aKlein, Stefan$$b19
000124452 7001_ $$aHo, Anthony D$$b20
000124452 7001_ $$aGoldschmidt, Hartmut$$b21
000124452 7001_ $$aWuchter, Patrick$$b22
000124452 773__ $$0PERI:(DE-600)2027114-1$$a10.1111/ejh.12888$$gVol. 99, no. 1, p. 42 - 50$$n1$$p42 - 50$$tEuropean journal of haematology$$v99$$x0902-4441$$y2017
000124452 909CO $$ooai:inrepo02.dkfz.de:124452$$pVDB
000124452 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000124452 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ecb33fb615e08035fdcefcaebfdff8f0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000124452 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000124452 9141_ $$y2017
000124452 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J HAEMATOL : 2015
000124452 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000124452 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000124452 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000124452 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000124452 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000124452 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000124452 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000124452 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000124452 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000124452 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000124452 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000124452 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000124452 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000124452 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000124452 980__ $$ajournal
000124452 980__ $$aVDB
000124452 980__ $$aI:(DE-He78)C060-20160331
000124452 980__ $$aUNRESTRICTED